P3.01-08 Gender Differences in Lung Cancer Survival

Abstract

reached) and median progression-free survival (PFS) was 17.8 months (95 CI: 13.1-24.2). Median OS was 37.2 months and not reached whereas median PFS was 14.2 months and 22 months in patients treated with upfront chemotherapy (n¼24) and with upfront ALK-inhibitor (n¼32), respectively. 2 nd line PFS was 22.6 months among patients (n¼13) treated with 2 nd line treatment. On multivariate analysis, gender (p¼0.007) and upfront treatment regimen (p¼0.001) emerged as independent prognostic factors for PFS whereas performance status (p¼0.02) and upfront treatment regimen (p¼0.01) showed significance for OS. Table 1: Baseline clinical characteristics and treatment details (n¼78) Conclusion: Primary tumor size was small with higher nodal burden and brain metastases in our cohort. Outcome was excellent with use of ALK-inhibitors in our series. Female sex and upfront use of ALK-inhibitors showed superior PFS whereas as good performance status and upfront use of ALK-inhibitors showed superior OS.